NASDAQ:GLMD

Galmed Pharmaceuticals Competitors

$3.07
-0.11 (-3.46 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$3.03
Now: $3.07
$3.19
50-Day Range
$3.18
MA: $3.54
$4.11
52-Week Range
$2.96
Now: $3.07
$6.29
Volume279,103 shs
Average Volume380,599 shs
Market Capitalization$77.01 million
P/E RatioN/A
Dividend YieldN/A
Beta2.3

Competitors

Galmed Pharmaceuticals (NASDAQ:GLMD) Vs. WVE, PRQR, IMUX, TRVN, CBAY, and ABUS

Should you be buying GLMD stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Galmed Pharmaceuticals, including Wave Life Sciences (WVE), ProQR Therapeutics (PRQR), Immunic (IMUX), Trevena (TRVN), CymaBay Therapeutics (CBAY), and Arbutus Biopharma (ABUS).

Galmed Pharmaceuticals (NASDAQ:GLMD) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk and Volatility

Galmed Pharmaceuticals has a beta of 2.3, meaning that its stock price is 130% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Galmed Pharmaceuticals and Wave Life Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galmed Pharmaceuticals02502.71
Wave Life Sciences02202.50

Galmed Pharmaceuticals currently has a consensus price target of $18.1429, suggesting a potential upside of 490.97%. Wave Life Sciences has a consensus price target of $11.80, suggesting a potential upside of 88.20%. Given Galmed Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Galmed Pharmaceuticals is more favorable than Wave Life Sciences.

Insider and Institutional Ownership

31.5% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.7% of Wave Life Sciences shares are owned by institutional investors. 38.2% of Wave Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Galmed Pharmaceuticals and Wave Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galmed Pharmaceuticals$2.04 million37.75$-20,460,000.00($0.97)-3.16
Wave Life Sciences$15.98 million19.22$-193,640,000.00($5.72)-1.10

Galmed Pharmaceuticals has higher earnings, but lower revenue than Wave Life Sciences. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Wave Life Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Galmed Pharmaceuticals and Wave Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Galmed PharmaceuticalsN/A-43.28%-39.33%
Wave Life Sciences-1,562.01%-401.32%-72.82%

Summary

Galmed Pharmaceuticals beats Wave Life Sciences on 10 of the 14 factors compared between the two stocks.

ProQR Therapeutics (NASDAQ:PRQR) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Institutional & Insider Ownership

55.9% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 31.5% of Galmed Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for ProQR Therapeutics and Galmed Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProQR Therapeutics00503.00
Galmed Pharmaceuticals02502.71

ProQR Therapeutics currently has a consensus price target of $32.6667, indicating a potential upside of 444.44%. Galmed Pharmaceuticals has a consensus price target of $18.1429, indicating a potential upside of 490.97%. Given Galmed Pharmaceuticals' higher probable upside, analysts plainly believe Galmed Pharmaceuticals is more favorable than ProQR Therapeutics.

Earnings & Valuation

This table compares ProQR Therapeutics and Galmed Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProQR TherapeuticsN/AN/A$-63,560,000.00($1.55)-3.87
Galmed Pharmaceuticals$2.04 million37.75$-20,460,000.00($0.97)-3.16

Galmed Pharmaceuticals has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

ProQR Therapeutics has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 2.3, indicating that its stock price is 130% more volatile than the S&P 500.

Profitability

This table compares ProQR Therapeutics and Galmed Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProQR TherapeuticsN/A-62.92%-47.69%
Galmed PharmaceuticalsN/A-43.28%-39.33%

Summary

Galmed Pharmaceuticals beats ProQR Therapeutics on 8 of the 10 factors compared between the two stocks.

Immunic (NASDAQ:IMUX) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.

Risk and Volatility

Immunic has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 2.3, indicating that its share price is 130% more volatile than the S&P 500.

Earnings & Valuation

This table compares Immunic and Galmed Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunicN/AN/A$-34,930,000.00($4.52)-3.14
Galmed Pharmaceuticals$2.04 million37.75$-20,460,000.00($0.97)-3.16

Galmed Pharmaceuticals has higher revenue and earnings than Immunic. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Immunic and Galmed Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunic001003.00
Galmed Pharmaceuticals02502.71

Immunic currently has a consensus price target of $59.5556, indicating a potential upside of 319.11%. Galmed Pharmaceuticals has a consensus price target of $18.1429, indicating a potential upside of 490.97%. Given Galmed Pharmaceuticals' higher possible upside, analysts plainly believe Galmed Pharmaceuticals is more favorable than Immunic.

Profitability

This table compares Immunic and Galmed Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunicN/A-46.33%-42.50%
Galmed PharmaceuticalsN/A-43.28%-39.33%

Insider & Institutional Ownership

41.3% of Immunic shares are owned by institutional investors. Comparatively, 31.5% of Galmed Pharmaceuticals shares are owned by institutional investors. 12.1% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Galmed Pharmaceuticals beats Immunic on 8 of the 12 factors compared between the two stocks.

Trevena (NASDAQ:TRVN) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Volatility and Risk

Trevena has a beta of 2.59, suggesting that its stock price is 159% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 2.3, suggesting that its stock price is 130% more volatile than the S&P 500.

Earnings & Valuation

This table compares Trevena and Galmed Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$30,000.009,998.99$-24,870,000.00($0.27)-6.89
Galmed Pharmaceuticals$2.04 million37.75$-20,460,000.00($0.97)-3.16

Galmed Pharmaceuticals has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

11.6% of Trevena shares are held by institutional investors. Comparatively, 31.5% of Galmed Pharmaceuticals shares are held by institutional investors. 5.2% of Trevena shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Trevena and Galmed Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TrevenaN/A-42.49%-34.83%
Galmed PharmaceuticalsN/A-43.28%-39.33%

Analyst Recommendations

This is a summary of current recommendations and price targets for Trevena and Galmed Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trevena01302.75
Galmed Pharmaceuticals02502.71

Trevena currently has a consensus price target of $5.00, suggesting a potential upside of 168.82%. Galmed Pharmaceuticals has a consensus price target of $18.1429, suggesting a potential upside of 490.97%. Given Galmed Pharmaceuticals' higher probable upside, analysts clearly believe Galmed Pharmaceuticals is more favorable than Trevena.

Summary

Trevena beats Galmed Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

CymaBay Therapeutics (NASDAQ:CBAY) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Insider and Institutional Ownership

84.3% of CymaBay Therapeutics shares are held by institutional investors. Comparatively, 31.5% of Galmed Pharmaceuticals shares are held by institutional investors. 4.0% of CymaBay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares CymaBay Therapeutics and Galmed Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CymaBay TherapeuticsN/AN/A$-102,810,000.00($1.46)-2.96
Galmed Pharmaceuticals$2.04 million37.75$-20,460,000.00($0.97)-3.16

Galmed Pharmaceuticals has higher revenue and earnings than CymaBay Therapeutics. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than CymaBay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for CymaBay Therapeutics and Galmed Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CymaBay Therapeutics001113.08
Galmed Pharmaceuticals02502.71

CymaBay Therapeutics currently has a consensus target price of $11.7692, indicating a potential upside of 172.44%. Galmed Pharmaceuticals has a consensus target price of $18.1429, indicating a potential upside of 490.97%. Given Galmed Pharmaceuticals' higher probable upside, analysts plainly believe Galmed Pharmaceuticals is more favorable than CymaBay Therapeutics.

Volatility & Risk

CymaBay Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 2.3, suggesting that its share price is 130% more volatile than the S&P 500.

Profitability

This table compares CymaBay Therapeutics and Galmed Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CymaBay TherapeuticsN/A-34.86%-32.23%
Galmed PharmaceuticalsN/A-43.28%-39.33%

Summary

CymaBay Therapeutics beats Galmed Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Galmed Pharmaceuticals (NASDAQ:GLMD) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Valuation and Earnings

This table compares Galmed Pharmaceuticals and Arbutus Biopharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galmed Pharmaceuticals$2.04 million37.75$-20,460,000.00($0.97)-3.16
Arbutus Biopharma$6.01 million49.21$-153,720,000.00($1.62)-1.90

Galmed Pharmaceuticals has higher earnings, but lower revenue than Arbutus Biopharma. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

31.5% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.4% of Arbutus Biopharma shares are owned by institutional investors. 6.7% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Galmed Pharmaceuticals and Arbutus Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Galmed PharmaceuticalsN/A-43.28%-39.33%
Arbutus Biopharma-1,163.48%N/A-59.66%

Volatility and Risk

Galmed Pharmaceuticals has a beta of 2.3, indicating that its share price is 130% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 3.15, indicating that its share price is 215% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Galmed Pharmaceuticals and Arbutus Biopharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galmed Pharmaceuticals02502.71
Arbutus Biopharma02502.71

Galmed Pharmaceuticals currently has a consensus target price of $18.1429, indicating a potential upside of 490.97%. Arbutus Biopharma has a consensus target price of $6.50, indicating a potential upside of 111.73%. Given Galmed Pharmaceuticals' higher possible upside, research analysts clearly believe Galmed Pharmaceuticals is more favorable than Arbutus Biopharma.

Summary

Galmed Pharmaceuticals beats Arbutus Biopharma on 7 of the 12 factors compared between the two stocks.


Galmed Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Wave Life Sciences logo
WVE
Wave Life Sciences
1.8$6.27-1.1%$307.21 million$15.98 million-1.11Decrease in Short Interest
News Coverage
ProQR Therapeutics logo
PRQR
ProQR Therapeutics
1.4$6.00-3.0%$301.23 millionN/A-4.88Increase in Short Interest
Immunic logo
IMUX
Immunic
1.8$14.21-8.7%$300.80 millionN/A-4.82Analyst Report
Increase in Short Interest
News Coverage
Gap Down
Trevena logo
TRVN
Trevena
1.3$1.86-21.0%$299.97 million$30,000.00-8.09High Trading Volume
News Coverage
Gap Up
CymaBay Therapeutics logo
CBAY
CymaBay Therapeutics
1.6$4.32-0.0%$297.85 millionN/A-4.60
Arbutus Biopharma logo
ABUS
Arbutus Biopharma
1.4$3.07-4.2%$295.75 million$6.01 million-2.50Gap Down
VistaGen Therapeutics logo
VTGN
VistaGen Therapeutics
1.3$2.05-2.9%$293.85 millionN/A-4.27Analyst Upgrade
Decrease in Short Interest
News Coverage
Sol-Gel Technologies logo
SLGL
Sol-Gel Technologies
1.2$14.36-2.4%$292.80 million$22.90 million-10.80
TFF Pharmaceuticals logo
TFFP
TFF Pharmaceuticals
1.4$12.07-0.5%$279.30 millionN/A-4.57Increase in Short Interest
Kezar Life Sciences logo
KZR
Kezar Life Sciences
1.3$5.74-3.7%$275.90 millionN/A-4.59News Coverage
Gap Down
Kamada logo
KMDA
Kamada
1.4$6.17-2.6%$274.69 million$127.19 million12.85News Coverage
Gap Down
VYNE Therapeutics logo
VYNE
VYNE Therapeutics
1.8$5.35-2.2%$274.35 million$10.64 million-1.43
Infinity Pharmaceuticals logo
INFI
Infinity Pharmaceuticals
1.6$2.98-3.4%$264.15 million$3.05 million-4.20Analyst Upgrade
Gap Down
Alpine Immune Sciences logo
ALPN
Alpine Immune Sciences
1.8$11.00-2.5%$262.70 million$1.74 million-7.64Insider Selling
News Coverage
NextCure logo
NXTC
NextCure
1.6$9.42-0.5%$259.99 million$6.35 million-8.34
Mustang Bio logo
MBIO
Mustang Bio
1.6$3.05-3.9%$259.78 millionN/A-2.44Increase in Short Interest
Gap Down
Immunome logo
IMNM
Immunome
1.0$24.06-9.3%$256.48 millionN/A0.00Analyst Upgrade
Gap Down
TLC
Taiwan Liposome
1.2$5.99-4.8%$252.04 million$6.99 million-7.49Gap Down
Ovid Therapeutics logo
OVID
Ovid Therapeutics
1.5$3.78-1.1%$248.55 millionN/A-2.68Analyst Downgrade
Decrease in Short Interest
News Coverage
Oramed Pharmaceuticals logo
ORMP
Oramed Pharmaceuticals
1.3$8.45-3.9%$248.18 million$2.71 million-14.57Earnings Announcement
News Coverage
Gap Down
9 Meters Biopharma logo
NMTR
9 Meters Biopharma
1.8$1.10-1.8%$237.68 millionN/A0.00
Tricida logo
TCDA
Tricida
1.9$4.68-9.0%$235.14 millionN/A-0.87Analyst Downgrade
News Coverage
Gap Down
Xeris Pharmaceuticals logo
XERS
Xeris Pharmaceuticals
1.6$3.91-1.3%$233.68 million$2.72 million-0.98Increase in Short Interest
PLx Pharma logo
PLXP
PLx Pharma
1.5$10.61-1.1%$231.16 million$570,000.00-8.63Analyst Upgrade
News Coverage
Gap Down
Mereo BioPharma Group logo
MREO
Mereo BioPharma Group
1.4$3.35-0.6%$227.10 millionN/A-1.35Analyst Downgrade
Increase in Short Interest
News Coverage
Cerecor logo
CERC
Cerecor
1.8$2.51-3.6%$223.65 million$6.75 million-8.37Gap Down
vTv Therapeutics logo
VTVT
vTv Therapeutics
1.2$2.71-8.1%$218.60 million$2.76 million-6.16Gap Down
MediciNova logo
MNOV
MediciNova
1.2$4.49-3.6%$218.58 millionN/A0.00Upcoming Earnings
News Coverage
Citius Pharmaceuticals logo
CTXR
Citius Pharmaceuticals
1.3$1.73-1.2%$217.61 millionN/A0.00Increase in Short Interest
News Coverage
Corbus Pharmaceuticals logo
CRBP
Corbus Pharmaceuticals
1.7$1.72-2.3%$215.06 million$36.14 million-0.96News Coverage
Checkpoint Therapeutics logo
CKPT
Checkpoint Therapeutics
1.2$2.85-4.2%$214.35 million$1.71 million-6.20News Coverage
Immutep logo
IMMP
Immutep
1.3$3.29-2.4%$213.43 million$4.92 million0.00Increase in Short Interest
Medicenna Therapeutics logo
MDNA
Medicenna Therapeutics
0.7$3.97-0.0%$210.23 millionN/A-19.85Increase in Short Interest
Analyst Revision
Sierra Oncology logo
SRRA
Sierra Oncology
1.8$17.93-2.6%$208.49 millionN/A-1.28Increase in Short Interest
Gap Down
NuCana logo
NCNA
NuCana
1.5$4.29-1.2%$208.04 millionN/A-4.25
Harrow Health logo
HROW
Harrow Health
1.4$8.00-8.8%$207.86 million$51.17 million-100.00High Trading Volume
News Coverage
Osmotica Pharmaceuticals logo
OSMT
Osmotica Pharmaceuticals
1.1$3.27-3.7%$204.65 million$240.03 million-3.55Gap Up
Anchiano Therapeutics logo
ANCN
Anchiano Therapeutics
0.8$27.26-23.2%$202.27 millionN/A181.73Gap Down
Kindred Biosciences logo
KIN
Kindred Biosciences
1.6$4.85-2.5%$201.03 million$4.26 million-7.03
Tyme Technologies logo
TYME
Tyme Technologies
1.3$1.53-0.7%$199.55 millionN/A-6.95
Neptune Wellness Solutions logo
NEPT
Neptune Wellness Solutions
1.3$1.20-2.5%$198.66 million$22.05 million-2.40
Eton Pharmaceuticals logo
ETON
Eton Pharmaceuticals
1.3$8.08-5.9%$197.22 million$460,000.00-6.79News Coverage
Lannett logo
LCI
Lannett
2.0$4.76-0.2%$197.07 million$545.74 million-6.61
Atossa Therapeutics logo
ATOS
Atossa Therapeutics
1.2$1.63-6.1%$196.94 millionN/A-1.21Increase in Short Interest
News Coverage
Iterum Therapeutics logo
ITRM
Iterum Therapeutics
1.3$1.10-4.5%$194.13 million$40,000.00-0.27Analyst Upgrade
Decrease in Short Interest
Gap Up
Equillium logo
EQ
Equillium
1.9$6.64-0.8%$192.83 millionN/A-4.23
CTI BioPharma logo
CTIC
CTI BioPharma
1.7$2.46-1.2%$188.65 million$3.35 million-3.62Gap Up
Galera Therapeutics logo
GRTX
Galera Therapeutics
1.6$7.53-3.2%$188.07 millionN/A-2.16
IMV logo
IMV
IMV
0.8$2.77-0.7%$187.33 million$430,000.00-6.02
OptiNose logo
OPTN
OptiNose
1.6$3.51-2.3%$185.84 million$34.63 million-1.60News Coverage
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.